FOXP3 and breast cancer: In particular, the presence of CD4+FOXP3+ TILs has been consistently associated with poor outcome in retrospective series of early luminal-like BC patients receiving endocrine treatment with selective estrogen receptor modulators (SERMs, such as tamoxifen), especially in the absence of concurrent CD8+ TIL infiltration [48,68].